Thoracic Cancer Research

Thoracic Cancer Research

Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.

Clinical Trials

Repository of Lung Cancer Diagnostic Procedure Images
Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
S1827 A randomized Phase III trial comparing prophylactic cranial irradiation (PCI) for any patient with small cell lung cancer (either extensive or limited stage) to active surveillance with MRI in place of PCI
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
DuRvalumab MEDI4730 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma A phase 3 Randomised trial (DREAM3R)
Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK- rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Disease Team Members

First Name Last Name Title Role
Chandra Belani, MD Chandra Belani MD View Researcher Profile
Mitchell Machtay, MD Mitchell Machtay MD View Researcher Profile
Rickhesvar Mahraj, MD, FRCP, FRCR Rickhesvar Mahraj MD, FRCP, FRCR View Researcher Profile
Michael F. Reed, MD Michael F. Reed MD View Researcher Profile
Matthew D. Taylor, MD Matthew D. Taylor MD View Researcher Profile
Jennifer Toth, MD Jennifer Toth MD View Researcher Profile
Leonard Tuanquin, MD Leonard Tuanquin MD View Researcher Profile
Research into thoracic cancer at Penn State Cancer Institute is conducted by our dedicated thoracic cancer team. See current clinical trials and members of that team here.
Repository of Lung Cancer Diagnostic Procedure Images
Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
S1827 A randomized Phase III trial comparing prophylactic cranial irradiation (PCI) for any patient with small cell lung cancer (either extensive or limited stage) to active surveillance with MRI in place of PCI
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
DuRvalumab MEDI4730 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma A phase 3 Randomised trial (DREAM3R)
Phase Ib Study of Brigatinib Plus Bevacizumab in Patients with ALK- rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)